Each year, World Pancreatic Cancer Day is observed to raise awareness of one of the most silent and aggressive tumors. It is a day to highlight that, although it is not frequently discussed, its impact on public health is highly significant.
Global Objectives of the Campaign: Awareness, Diagnosis and Hope
The main aims of this campaign are:
- To increase visibility of this type of cancer among the general population and healthcare professionals.
- To promote early detection and diagnosis at the earliest possible stages.
- To foster hope by sharing advances in treatment, research and improvements in clinical outcomes.
The Role of Awareness and Research in Improving Survival
Public awareness and support for biomedical research are key. When more people and professionals understand risk factors, early symptoms and available resources, diagnostic pathways can be activated sooner. Research, in turn, enables the development of new therapies and surgical strategies that improve survival.
Pancreatic Cancer in Spain: Current Data and Context
Incidence and Mortality According to REDECAN and SEOM
- According to the Spanish Society of Medical Oncology (SEOM), an estimated 10,338 new cases of pancreatic cancer are expected in Spain in 2025.
- The Spanish Network of Cancer Registries (REDECAN) also reports a rising incidence of pancreatic cancer in both men and women.
Why It Remains One of the Deadliest Tumors
Although its incidence is lower than that of other common tumors, its mortality is very high. SEOM notes that at the time of diagnosis, only about 20% of patients are candidates for curative surgical resection.
Pancreatic cancer is currently the fifth leading cause of cancer-related death, and it is estimated that by 2030 it will become the second. This striking figure reflects that research and targeted therapies in other cancers are advancing much faster than in pancreatic cancer.
Factors Behind Late Diagnosis
Late diagnosis is attributable to:
- Nonspecific symptoms in early stages (such as indigestion, vague pain, weight loss).
- The deep retroperitoneal location and anatomy of the pancreas, which make early detection difficult before the tumor progresses.
- Limitations in population-wide screening, as there is no screening program for the general population.
Risk Factors and Prevention
Main Risk Factors (Smoking, Obesity, Diabetes, Genetics, Age)
Recognized risk factors include:
- Smoking: about 30% of cases may be linked to tobacco use.
- Obesity and type 2 diabetes: increasing prevalence contributes to higher risk.
- Age: most diagnoses occur between ages 65 and 70.
- Alcohol consumption and recurrent chronic pancreatitis.
- Genetic/hereditary factors: 5–10% of cases may be associated with germline mutations (e.g., BRCA1/2) or hereditary syndromes.
Primary Prevention: Healthy Lifestyle Habits Backed by Scientific Evidence
Risk reduction measures include:
- Avoiding tobacco use.
- Maintaining a healthy body weight and following a balanced diet rich in fruits and vegetables and low in processed foods.
- Regular physical activity.
- Proper management of diabetes and other metabolic diseases.
Secondary Prevention: Monitoring High-Risk Groups and Hereditary Syndromes
For individuals at high risk (family history, genetic mutations, chronic pancreatitis):
- Periodic evaluation by specialists in digestive oncology and genetics.
- Potential follow-up with specific tests in specialized centers.
- Patient education about warning signs and fast-track evaluation pathways.
Early Detection: The Main Challenge
Symptoms That May Raise Concern
Warning signs that should not be ignored include:
- Jaundice (yellowing of skin and eyes) when the tumor obstructs the bile duct.
- Persistent abdominal pain or pain radiating to the back.
- Unexplained weight loss, loss of appetite, heavy digestion or recent abnormalities in glucose control.
Why Pancreatic Cancer Is Diagnosed Late
Diagnostic delays may occur due to:
- Nonspecific symptoms that are often attributed to benign conditions.
- Rapid tumor progression before clear symptoms appear.
- Lack of systematic screening for the general population.
Current Diagnostic Tools: Imaging, Biomarkers and Endoscopic Ultrasound
Diagnostic assessment includes:
- Imaging tests: CT scans and MRI.
- Biomarkers: such as CA 19-9, though it is not specific or definitive on its own.
- Endoscopic ultrasound with possible biopsy, performed in specialized centers.
Importance of Multidisciplinary Units for Fast and Precise Diagnosis
A multidisciplinary unit (surgery, oncology, radiology, pathology, genetics) ensures:
- Joint evaluation of each patient.
- Rapid and appropriate therapeutic decision-making.
- Optimal planning of surgical intervention or neoadjuvant treatment.
Recent Advances in Pancreatic Cancer Treatment
Innovations in Surgery: Resection and Minimally Invasive Techniques
Surgery remains the only potentially curative treatment for pancreatic cancer when complete resection is possible. Major recent innovations aim to improve outcomes and reduce procedure-related aggressiveness:
- Minimally invasive surgery (laparoscopic and robotic): allows more precise resections, less blood loss, less postoperative pain and faster recovery.
- Complex vascular resection: in selected cases, mesenteric or portal vessel reconstruction can expand surgical options for locally advanced tumors.
- Local ablation techniques: such as percutaneous radiofrequency or microwave ablation, and irreversible electroporation (IRE), which use heat or electrical pulses to destroy tumor cells without damaging nearby vessels or bile ducts. These are especially useful for unresectable locally advanced tumors or as complementary treatments after surgery or chemotherapy. IRE is particularly advantageous near major vessels, where conventional surgery or thermal ablation may not be safe.
At specialized centers like IVOQA, these technologies are integrated into a multidisciplinary approach combining advanced surgery, medical oncology, interventional radiology and personalized planning.
New Chemotherapy Combinations and Targeted Therapies
Chemotherapy protocols have evolved with more active first-line combinations, and in certain patients, targeted therapies based on the tumor’s genomic profile.
Precision Medicine and Tumor Genomic Analysis
Precision medicine helps identify mutations (such as BRCA), allowing maintenance therapies for selected patients. For example, pancreatic tumors with BRCA mutations may benefit from PARP inhibitors.
Research in Immunotherapy and Developing Therapies
Although results with immunotherapy have been limited so far in pancreatic cancer, new clinical trials are exploring combinations with cell therapies and tumor microenvironment modulators. Some patients with PD-L1 expression may benefit from targeted immunotherapies.
The Multidisciplinary Approach at IVOQA
Specialized Team With Integrated Care
At the Viamed Institute of Advanced Surgical Oncology (IVOQA), our specialized team in digestive oncology, pancreatic surgery, medical oncology, radiology and interventional radiology works together to provide comprehensive care.
Rapid Diagnosis, Advanced Technology and Personalized Planning
We have cutting-edge diagnostic equipment (imaging, endoscopic ultrasound, reference pathology) and design personalized treatment plans to maximize each patient’s chances of success.
Comprehensive Support: Medical, Psychological and Human Care
Beyond clinical treatment, IVOQA offers psychological support, patient and family guidance, and assistance with logistical aspects (international patients, follow-up), because each person is unique.
World Pancreatic Cancer Day reminds us that research, prevention and early diagnosis are essential to changing the outlook of this disease. At IVOQA, we reaffirm our role as a leader in oncological innovation, advanced surgery and precision medicine, and we call on society to:
- Address risk factors and adopt healthy lifestyle habits.
- Stay alert to symptoms and consult a specialist early when discomfort persists.
- Support research through awareness, education and collective action.
Together, we can build a future with lower mortality and greater hope in pancreatic cancer.
